Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Nuvasive on Wednesday, setting a price target of $68, which is approximately 27.25% above the present share price of $53.44.
Rose expects Nuvasive to post earnings per share (EPS) of -$0.98 for the fourth quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in NuVasive (NASDAQ:NUVA), with an average price target of $69.38.
The analysts price targets range from a high of $78 to a low of $53.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $203.61 million and a net profit of -$35.42 million. The company's market cap is $2.74 billion.
According to TipRanks.com, Canaccord Genuity analyst Kyle Rose is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 10.8% and a 52.12% success rate.
NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.